The efficacy, safety, and tolerability of centanafadine SR (200 mg TDD or 400 mg TDD) compared to placebo for the treatment of adults with ADHD
Charlotte, North CarolinaView PDF
End Date January 30, 2020
Primary Contact Dr. Anelys Marin, BS, CCRC, RMA, IMG
Phone (980) 209-9784 ext. 2012
Social Media View
Purpose of the Study:
To confirm the efficacy of centanafadine sustained-release (SR) tablets administered twice-daily (BID; 200 mg or 400 mg total daily doses [TDDs]) compared to placebo in the treatment of adults with ADHD.
To confirm the safety and tolerability of centanafadine SR tablets administered BID (200 mg or 400 mg TDDs) compared to placebo in the treatment of adults with ADHD.